ReviewCurrent treatment options in allergy
Monitoring Allergen Immunotherapy Effects by Microarray.
Review in Current treatment options in allergy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Maternal allergen-specific IgG might protect the child against allergic sensitization.The Journal of allergy and clinical immunology · 2019Trial
- Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.EBioMedicine · 2016Trial
- Quantum Dot Bioconjugates Enable Order(s)-of-Magnitude Enhancement of Immunoglobulin E Detection Sensitivity.ACS omega · 2026Article
- Single-Domain Antibodies-Novel Tools to Study and Treat Allergies.International journal of molecular sciences · 2024Review
- Milk Allergen Micro-Array (MAMA) for Refined Detection of Cow's-Milk-Specific IgE Sensitization.Nutrients · 2023Article
- Review
- MustSeq, an alternative approach for multiplexible strand-specific 3' end sequencing of mRNA transcriptome confers high efficiency and practicality.RNA biology · 2021Article
- Effectiveness and safety of oral lactococci-based vaccine encoding triple common allergens to prevent airway allergy in mice.PloS one · 2021Article
- Nanobodies-Useful Tools for Allergy Treatment?Frontiers in immunology · 2020Review
- Microarray-Based Allergy Diagnosis: Quo Vadis?Frontiers in immunology · 2020Review
- Two grass pollen tablets commercially available for allergy immunotherapy display different IgE epitope repertoires.Clinical and translational allergy · 2019Article
- The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses.Clinical reviews in allergy & immunology · 2018Review
- Impact of allergen immunotherapy in allergic asthma.Immunotherapy · 2018Review
- Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT.Clinical and translational allergy · 2018Article
- The culprit insect but not severity of allergic reactions to bee and wasp venom can be determined by molecular diagnosis.PloS one · 2018Article
- Detection of IgE Reactivity to a Handful of Allergen Molecules in Early Childhood Predicts Respiratory Allergy in Adolescence.EBioMedicine · 2017Article
- Recombinant allergy vaccines based on allergen-derived B cell epitopes.Immunology letters · 2017Review
- Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2017Review
- Human Immune Monitoring Techniques during Food Allergen Immunotherapy.Current allergy and asthma reports · 2017Review
- [Molecular-allergological aspects of allergen-specific immunotherapy].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen-specific immunotherapy (AIT) is the only treatment of IgE-mediated allergies so far that has a sustained effect on clinical symptoms and can modify the course of the disease. It is an allergen-specific treatment and therefore requires the correct identification of the disease-causing allergens. Furthermore, AIT is a time-consuming treatment for which the efficacy is dependent on several factors. Therefore, diagnostic tests and biomarkers are needed that facilitate (1) selection of the correct allergens according to the patient's individual sensitization profile and (2) to monitor the effects of AIT. This can provide support for the decision to continue, modify, or discontinue vaccination. One significant mechanism of action of AIT is the induction of allergen-specific antibodies that compete with IgE for the binding to allergen molecules, hence referred to as blocking antibodies. It was shown in several studies that the induction of blocking antibodies by AIT, and their specificity can be measured by allergen microarrays. Inhibition of allergen-specific IgE binding by blocking antibodies can also be determined by microarrays and is associated with changes in clinical parameters or other in vivo and in vitro assays demonstrating efficacy of AIT. Furthermore, allergen microarrays allow determination of IgE sensitizations towards a comprehensive set of allergen molecules and therefore are well suited for identifying the disease-causing allergens for correct prescription of AIT. Thus, diagnostic tests based on microarrayed allergens can be useful in determining the correct prescription of AIT and can be used to monitor efficacy of AIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.